[go: up one dir, main page]

DE60305443D1 - Pharmazeutische zusammnesetzung zur verbesserten in-vivo genübertragung - Google Patents

Pharmazeutische zusammnesetzung zur verbesserten in-vivo genübertragung

Info

Publication number
DE60305443D1
DE60305443D1 DE60305443T DE60305443T DE60305443D1 DE 60305443 D1 DE60305443 D1 DE 60305443D1 DE 60305443 T DE60305443 T DE 60305443T DE 60305443 T DE60305443 T DE 60305443T DE 60305443 D1 DE60305443 D1 DE 60305443D1
Authority
DE
Germany
Prior art keywords
pharmaceutical composition
improved
general transmission
vivo general
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60305443T
Other languages
English (en)
Other versions
DE60305443T2 (de
Inventor
Bruno Pitard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Application granted granted Critical
Publication of DE60305443D1 publication Critical patent/DE60305443D1/de
Publication of DE60305443T2 publication Critical patent/DE60305443T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE60305443T 2002-02-08 2003-02-07 Pharmazeutische zusammnesetzung zur verbesserten in-vivo genübertragung Expired - Lifetime DE60305443T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0201584A FR2835749B1 (fr) 2002-02-08 2002-02-08 Composition pharmaceutique ameliorant le transfert de gene in vivo
FR0201584 2002-02-08
PCT/FR2003/000407 WO2003066104A2 (fr) 2002-02-08 2003-02-07 Composition pharmaceutique ameliorant le transfert de gene in vivo

Publications (2)

Publication Number Publication Date
DE60305443D1 true DE60305443D1 (de) 2006-06-29
DE60305443T2 DE60305443T2 (de) 2007-05-10

Family

ID=27620039

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60305443T Expired - Lifetime DE60305443T2 (de) 2002-02-08 2003-02-07 Pharmazeutische zusammnesetzung zur verbesserten in-vivo genübertragung

Country Status (10)

Country Link
US (2) US7709452B2 (de)
EP (1) EP1471944B1 (de)
JP (1) JP4613011B2 (de)
AT (1) ATE326986T1 (de)
AU (1) AU2003222896A1 (de)
CA (1) CA2473212C (de)
DE (1) DE60305443T2 (de)
ES (1) ES2265569T3 (de)
FR (1) FR2835749B1 (de)
WO (1) WO2003066104A2 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2868953B1 (fr) * 2004-04-16 2006-06-30 Inst Nat Sante Rech Med Composition pour le transfert intracellulaire d'un acide nucleique.
KR20090054438A (ko) * 2006-09-15 2009-05-29 엔존 파마슈티컬즈, 인코포레이티드 양전하를 띄는 부분을 포함하는 고분자 컨쥬게이트
DE102006051623A1 (de) 2006-11-02 2008-07-31 Horn, Peter A. Verfahren und Stoffgemisch zur Verbesserung eines in vivo Genfransfers
WO2010026537A1 (en) 2008-09-05 2010-03-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) Novel multimodular assembly useful for intracellular delivery
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DE19177059T1 (de) 2010-10-01 2021-10-07 Modernatx, Inc. N1-methyl-pseudouracile enthältendes ribonucleinsäuren sowie ihre verwendungen
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
KR20190099538A (ko) 2011-10-03 2019-08-27 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드, 및 핵산, 및 이들의 용도
EP2791160B1 (de) 2011-12-16 2022-03-02 ModernaTX, Inc. Modifizierte mrna zusammensetzungen
WO2013106558A1 (en) 2012-01-10 2013-07-18 Merial Limited Lipid based adjuvants for dna - plasmid vaccines
WO2013128424A1 (en) 2012-03-02 2013-09-06 Institut National De La Sante Et De La Recherche Medicale Vaccine for prophylaxis or treatment of an allergen-driven and/or a chronic airways disease
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
CA2868393A1 (en) 2012-04-02 2013-10-10 Moderna Therapeutics, Inc. Modified polynucleotides for the production of oncology-related proteins and peptides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US20150182620A1 (en) 2012-06-15 2015-07-02 Inserm (Institut De La Sante Et De La Recherche Medicale) Polypeptides for use in the Prophylactic Treatment of Allergic Asthma
SI2922554T1 (sl) 2012-11-26 2022-06-30 Modernatx, Inc. Terminalno modificirana RNA
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
BR112016007255A2 (pt) 2013-10-03 2017-09-12 Moderna Therapeutics Inc polinucleotídeos que codificam receptor de lipoproteína de baixa densidade
ES2759243T3 (es) 2014-04-01 2020-05-08 Inst Nat Sante Rech Med Moléculas de ARN protegidas y no protegidas y copolímeros de bloques para la administración intracelular de ARN
EP3225246A1 (de) 2016-03-31 2017-10-04 Klinikum der Universität München Synthetische verbindung zur verbesserung der effizienz der transfektion
EP3762011A1 (de) 2018-03-05 2021-01-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren und zusammensetzung zur behandlung von allergischem asthma
US20220184191A1 (en) * 2019-03-11 2022-06-16 Evaxion Biotech A/S Nucleic acid vaccination using neo-epitope encoding constructs
AU2021202658A1 (en) 2021-04-28 2022-11-17 Fondazione Telethon Gene therapy
GB202206346D0 (en) 2022-04-29 2022-06-15 Ospedale San Raffaele Srl Gene therapy
WO2024200829A1 (en) 2023-03-30 2024-10-03 Vivadju Pvax14 nucleic acid formulated with nano-vehicle in combination with all-trans retinoic acid (atra) for activating immune pathways
WO2024200831A1 (en) 2023-03-30 2024-10-03 Vivadju Pvax14 nucleic acid in combination with all-trans retinoic acid (atra) and a checkpoint inhibitor for the treatment of cancer
WO2025129128A1 (en) 2023-12-15 2025-06-19 Vivasor, Inc. Compositions and methods for non-viral delivery of therapeutic compounds

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5470568A (en) * 1992-02-13 1995-11-28 Arch Development Corporation Methods and compositions of a polymer (poloxamer) for cell repair
GB9216082D0 (en) * 1992-07-28 1992-09-09 Univ Nottingham Lymphatic delivery composition
US5656611A (en) * 1994-11-18 1997-08-12 Supratek Pharma Inc. Polynucleotide compositions
US6221959B1 (en) * 1994-11-18 2001-04-24 Supratek Pharma, Inc. Polynucleotide compositions
US6359054B1 (en) * 1994-11-18 2002-03-19 Supratek Pharma Inc. Polynucleotide compositions for intramuscular administration
US6040295A (en) 1995-01-13 2000-03-21 Genemedicine, Inc. Formulated nucleic acid compositions and methods of administering the same for gene therapy
AU1922999A (en) * 1997-12-16 1999-07-05 Baylor College Of Medicine Needle-free injection of formulated nucleic acid molecules
GB9904627D0 (en) * 1999-03-02 1999-04-21 Danbiosyst Uk Polymer compositions for polynucleotide delivery
AU4898699A (en) 1999-07-16 2001-02-05 Reatech Phosphor addition in gasification
WO2001008709A1 (en) * 1999-07-28 2001-02-08 Valentis, Inc. Sonoporation of tumors
WO2001060415A1 (en) * 2000-02-18 2001-08-23 The Immune Response Corporation Methods and compositions for gene delivery
AU2001241958A1 (en) * 2000-03-03 2001-09-17 Valentis, Inc. Improved poloxamer and poloxamine compositions for nucleic acid delivery
CN1531422A (zh) 2000-10-20 2004-09-22 治疗局部缺血的基因转移配方及方法

Also Published As

Publication number Publication date
US20100179212A1 (en) 2010-07-15
US7709452B2 (en) 2010-05-04
EP1471944A2 (de) 2004-11-03
DE60305443T2 (de) 2007-05-10
AU2003222896A1 (en) 2003-09-02
FR2835749B1 (fr) 2006-04-14
JP2005522433A (ja) 2005-07-28
FR2835749A1 (fr) 2003-08-15
JP4613011B2 (ja) 2011-01-12
US8367631B2 (en) 2013-02-05
CA2473212C (fr) 2013-04-23
US20050152870A1 (en) 2005-07-14
ATE326986T1 (de) 2006-06-15
WO2003066104A3 (fr) 2004-03-25
CA2473212A1 (fr) 2003-08-14
ES2265569T3 (es) 2007-02-16
EP1471944B1 (de) 2006-05-24
AU2003222896A8 (en) 2003-09-02
WO2003066104A2 (fr) 2003-08-14

Similar Documents

Publication Publication Date Title
DE60305443D1 (de) Pharmazeutische zusammnesetzung zur verbesserten in-vivo genübertragung
BR0213802A (pt) Copolìmero útil para a preparação de géis de ácidos
BR0116004A (pt) Derivados de 6-o-carbamoil cetolida de eritromicina úteis como antibacterianos
DK1366104T3 (da) Miljömæssigt nedbrydelige polymere forbindelser, deres fremstilling og anvendelse som hot-melt klæbestof
TWI262795B (en) Adhesive composition and method for producing it
ATE548020T1 (de) Kombinationen für orale zusammensetzungen, ihre herstellung und verwendung
SE0300010D0 (sv) Novel Compounds
TR200401029T4 (tr) Asilfenil-üre türevleri, imalat yöntemleri ve ilaç maddesi olarak kullanımları
WO2006048330A8 (en) 11βετα-hsd1 inhibitors
CA2349227A1 (en) Substituted 2-phenylbenzimidazoles, the production thereof and their use
TR200101499T1 (tr) Azepinoindol türevleri, hazırlanmaları ve kullanımları.
WO2007089330A3 (en) Extreme environment surfactant compositions comprising hydrolysis resistant organomodified disiloxane surfactants
BR0109062A (pt) Inibidores de frutose-1,6-bisfosfatase de arila
PL1755606T3 (pl) Pochodne chinazolinonu użyteczne jako antagoniści receptora waniloidowego
DK0680257T3 (da) Stabile, væskeformige sammensætninger og deres anvendelse
ATE354622T1 (de) Flüssigkristallines medium
WO2006010560A3 (de) Physiologisch aktive zusammensetzung
BR0114873A (pt) Imidazopiridinas polissubstituìdas
UA93529C2 (ru) Соли и смеси 9-оксоакридин-10-уксусной кислоты c 1-алкиламино-1-дезоксиполиолами
BR0211903A (pt) Isoxazolopiridinonas
EP1052262A3 (de) Verfahren zur Herstellung von Silanolgruppe-enthaltende Organosiliziumverbindungen
CA2426613A1 (en) Hydrogelatinizer
TW200502235A (en) Novel benzo[1,2,5]thiadiazoles and pharmaceutical use thereof
WO2005055937A3 (en) Branched sulfates with improved odor properties and their use in personal care compositions
DE60203890D1 (de) Apfelsäureadditionssalze von terbinafin

Legal Events

Date Code Title Description
8364 No opposition during term of opposition